Introduction

Type 2 diabetes mellitus (T2DM), a subtype of diabetes mellitus, is a chronic metabolic disorder characterized by hyperglycemia, as a result of impaired beta cell function, along with a marked increase in the peripheral insulin resistance, either at the receptor or post-receptor levels, and a rise in the hepatic glucose output. Diabetes mellitus has been implicated as an independent causative factor of sensorineural hearing loss. Neuropathy, both central and peripheral, is an important complication of T2DM. Although diabetic neuropathy it manifests clinically much later in the course of the disease, yet its physiological evidence can be obtained much earlier with the help of electrophysiological tests. The electrophysiological testing reflects the bioelectric responses of the nervous system to sensory (somatosensory evoked potentials), auditory (brainstem auditory evoked potentials) or visual stimuli (visual evoked potentials).

Brainstem auditory evoked potentials (BAEP) are the potentials that are recorded in response to brief auditory stimulation to assess the conduction through the auditory pathway, up to the midbrain. BAEPs are

Abstract

Background: Diabetes mellitus represents a syndrome complex in which multiple organ systems, including the central nervous system, are affected. Aim: The study was conducted to determine the changes in the brainstem auditory evoked potentials in type 2 diabetes mellitus. Materials and Methods: A cross-sectional study was conducted on 126 diabetic males, aged 35-50 years, and 106 age-matched, healthy male volunteers. Brainstem auditory evoked potentials were recorded and the results were analyzed statistically using student's unpaired t-test. The data consisted of wave latencies I, II, III, IV, V and interpeak latencies I-III, III-V and I-V, separately for both ears. Results: The latency of wave IV was significantly delayed only in the right ear, while the latency of waves III, V and interpeak latencies III-V, I-V showed a significant delay bilaterally in diabetic males. However, no significant difference was found between diabetic and control subjects as regards to the latency of wave IV unilaterally in the left ear and the latencies of waves I, II and interpeak latency I-III bilaterally. Conclusion: Diabetes patients have an early involvement of central auditory pathway, which can be detected with fair accuracy with auditory evoked potential studies.

Keywords: Brainstem dysfunction, Diabetes, Diabetic neuropathy, Interpeak latency, Sensorineural hearing loss, Wave latency

Address for correspondence: Dr. Sharat Gupta, Hno# 849, SST Nagar, Rajpura Road, Patiala, Punjab, India. E-mail: sharatgupta29@yahoo.co.in

Original Article

Brainstem Auditory Evoked Potential Abnormalities in Type 2 Diabetes Mellitus

Sharat Gupta, Pooja Baweja¹, Shalu Mittal¹, Avnish Kumar¹, Kamal D Singh¹, Raghuvansh Sharma²

Departments of Physiology, Gian Sagar Medical College, Ramnagar, ¹Department of Physiology, ²Internal Medicine, Government Medical College, Patiala, Punjab, India

Access this article online

Quick Response Code:
Website: www.najms.org
DOI: 10.4103/1947-2714.106211
clinically very useful in assessing not only the severity of hearing defects in brainstem dysfunction but also in assessment of hearing in uncooperative patients and children.\(^{[11]}\) Typically the BAEPs comprise of five or more waveforms that are recorded within 10 msec of an acoustic stimulus. Wave I originates from peripheral portion of cranial nerve VIII (auditory nerve) near the cochlear nucleus. Wave II originates from cochlear nucleus, wave III from superior olivary nucleus, wave IV from lateral lemniscus and wave V from inferior colliculi in the midbrain.\(^{[8]}\) In the recent past, many studies similar to our own have been done worldwide, but the results reported by these, with respect to the BAEP changes in diabetes, have been quite variable.\(^{[9,10]}\) Also there is a paucity of data on the BAEP abnormalities in diabetics in India, which is primarily due to the lesser number of studies, which have been done here.

The aim of the present study was to assess the BAEP abnormalities in Indian males suffering from T2DM and to find whether any correlation exists between the observed abnormalities and the fasting blood glucose levels and duration of diabetes or not.

**Materials and Methods**

The study was conducted in the Department of Physiology in the institute from 2008-2010. The subjects were divided into two groups (i) the diabetic group, and (ii) the control group. The study protocol was approved by the ethical committee of the institute. Written consent was obtained from all the enrolled subjects after explaining them the details of the study in their own language.

The diabetic group comprised of 126 male patients attending the Endocrinology Outdoor clinic of the hospital, while the control group consisted of 106 age-matched male volunteers from among the paramedical and lower staff of the hospital.

**Inclusion criteria**

Among the first group, those with T2DM, aged 35-50 years and with no past/present or family history of ear diseases or deafness were included. The diagnostic method of T2DM was based on the criteria from the American Diabetes Association.\(^{[11]}\) None of the diabetics had a clinically overt neuropathy at the time of study. Among the controls, non-diabetic, age matched males who had no past/present or family history of ear disease or deafness and who were apparently healthy, were included. We did not include subjects over 50 years of age since this age group has an increased incidence of presbycusis, a type of sensorineural hearing loss.

**Exclusion criteria**

For both the groups, those males were excluded, who had a history of head/ear trauma, significant occupational noise exposure, intake of known ototoxic drugs (e.g., aminoglycosides) or any other medication that might affect normal functioning of the nervous system (e.g., antidepressants, antipsychotics, methyl dopa, etc), family history of deafness or any systemic illness that might affect the nervous system (uremia, stroke, hepatic encephalopathy, multiple sclerosis, thyroid disorders, anemia, meningitis, etc), history of tobacco chewing, chronic alcoholism or cigarette smoking, any ear surgery, radiotherapy or chemotherapy. In the control group, in addition to the above criteria, those males were also excluded, who gave a past/family history of diabetes.

**Medical and biochemical examination**

Prior to the BAEP recordings, all the males were made to undergo the following:

1. Detailed history by way of self administered questionnaires about medical history and lifestyle.
2. Detailed general physical and systemic examination.
3. Complete ENT checkup by way of otoscopic examination and tuning fork tests, to rule out peripheral hearing loss.
4. Serum urea, creatinine and fasting blood glucose (FBG) levels, which were assessed in the clinical biochemistry lab of the hospital.

**Brainstem auditory evoked potentials study**

It was performed as per the guidelines of the American Clinical Neurophysiological Society.\(^{[12]}\) BAEPs were recorded with an evoked potential machine (RMS EMG EP-II Channel, Recorders and Medicare Systems Pvt. Ltd. Chandigarh, India). Before starting the test, age was calculated to the nearest completed year. Standing height without shoes (in cm) and body weight with minimal clothing (in kgs), were also noted. The BAEP recordings were done in a semi-dark room with quiet surroundings. The subjects were made to sit comfortably in a chair, whose back was turned towards the recording machine. The participants were asked to avoid unnecessary movement and to remove all the metallic ornaments that they were wearing. The recording method for BAEP is summarized below:

Monaural stimulation (i.e., one ear at a time), in the form of “broad-band clicks”, the acoustic energy of which is spread over a wide range of audio frequencies, was given via headphones at the rates of 11.1 Hz, along with masking of sounds in the contralateral ear. Two thousand clicks were averaged by a filter setting of 100 and 3000 Hz. The clicks were given at an intensity of 60 dB level above the individual perceptual hearing threshold. The latter was estimated by using the ascending and descending
Statistical analysis

The data was analyzed statistically by using Statistical Package for Social Sciences version 13.0 (SPSS Inc. Chicago, US). Student’s unpaired t-test was used for the analysis. Pearson’s coefficient was also found between the BAEP waveforms and the duration of the disease and the fasting blood sugar (FBG) levels. The BAEP wave latencies and IPL were dependent variables while both the duration of diabetes and FBG were independent variables.

Results

There was no statistical significance between any of the basic data i.e., age, height and weight of males in diabetes and control groups. However, there was a statistically highly significant difference between the mean FBS levels of both the groups, the values being much higher in diabetic males. In our subjects, the duration of T2DM ranged from 1-15 years [Table 1].

Furthermore, since all corresponding mean BAEP wave latencies are comparable between right and left ear, in both diabetic and control subjects [Tables 2 and 3] thus, it is clear that the right-left latency asymmetry is within normal limits in both these groups.

A comparison between the mean values of the various wave latencies and IPLs was done separately for both the ears, in diabetics and controls [Table 4]. No significant association was found between the latencies of waves I and II in diabetics and controls, with either right ear or left ear stimulation. The latencies of waves III and V were, however, significantly higher in diabetics for both right ear, as well as left ear stimulation. The latency of wave IV was significantly higher in diabetics with right ear stimulation, while it was comparable between diabetics and controls in case of left ear stimulation.

As regards to the interpeak latency comparison, it was seen that while IPL I-III was comparable between both the groups with either right ear or left ear stimulation, the other two measures, i.e., IPL III-V and I-V were both significantly increased in diabetics with both right ear stimulation, as well as left ear stimulation.

Also, all the BAEP wave latencies showed a non-significant positive correlation with both the duration of diabetes and FBG levels [Table 5]. However, there is a stronger correlation of BAEP latencies with FBG levels, as suggested by higher ‘r’ values, than with the duration of diabetes.

### Table 1: Comparison of anthropometric data and fasting blood sugar levels in diabetic and control subjects

| Parameter                | Diabetics (n=126) | Controls (n=106) | P value |
|--------------------------|-------------------|-----------------|---------|
| Age (years)              | 45.7±6.3          | 46.8±6.11       | 0.89    |
| Height (cms)             | 160.1±5.83        | 160.7±6.95      | 0.93    |
| Weight (kgs)             | 66±9.32           | 64.6±9.21       | 0.74    |
| FBG (mg/dl)              | 119.8±16.75       | 79.5±6.12       | <0.001  |
| Duration of disease (years) | 5.68±3.16  | NA              | NA      |

* n: No. of subjects, *NA: Not applicable, †Highly significant (P<0.001)

### Table 2: Comparison of brainstem auditory evoked potentials latencies (in msec) between the right and left ear of males with T2DM

| BAEP latencies | Right ear Mean±SD | Left ear Mean±SD | P value |
|----------------|-------------------|-----------------|---------|
| I              | 1.64±0.42         | 1.68±0.38       | 0.87    |
| II             | 2.85±0.49         | 2.90±0.35       | 0.92    |
| III            | 3.78±0.53         | 3.74±0.36       | 0.27    |
| IV             | 5.01±0.56         | 4.92±0.35       | 1.29    |
| V              | 5.96±0.68         | 5.88±0.42       | 1.33    |
| I-III          | 2.08±0.29         | 2.05±0.31       | 0.34    |
| I-V            | 2.10±0.72         | 2.04±0.31       | 0.39    |
| I-V            | 4.15±0.71         | 4.10±0.37       | 1.26    |

*None of the differences between any of the latencies is statistically significant (P>0.05)

### Table 3: Comparison of brainstem auditory evoked potentials latencies (in msec) between the right and left ear of controls

| BAEP latencies | Right ear Mean±SD | Left ear Mean±SD | P value |
|----------------|-------------------|-----------------|---------|
| I              | 1.62±0.15         | 1.63±0.15       | 0.89    |
| II             | 2.79±0.21         | 2.80±0.19       | 0.67    |
| III            | 3.55±0.14         | 3.53±0.16       | 0.59    |
| IV             | 4.84±0.20         | 4.90±0.18       | 0.86    |
| V              | 5.39±0.17         | 5.46±0.23       | 1.34    |
| I-III          | 2.03±0.16         | 2.00±0.17       | 0.39    |
| III-V          | 1.84±0.16         | 1.82±0.23       | 0.76    |
| I-V            | 3.86±0.21         | 3.83±0.22       | 1.04    |

*None of the differences between any of the latencies is statistically significant (P>0.05)
Discussion

The results of our study have shown that the waves III, V and IPL III-V, I-V were significantly delayed bilaterally, while wave IV was significantly delayed unilaterally, in males with T2DM.

Our findings support the results obtained by Talebi et al.\[13\] regarding the significant delay in waves III, IV, V and IPL III-V in patients with diabetes mellitus. Our results also support the findings of Al-Azzawi et al.\[18\] and Gupta et al.\[19\] regarding the significant prolongation of latencies of waves III, V and IPL III-V, I-V in diabetics. However, we did not observe any delay in IPL I-III in diabetics, as reported by both these studies. Our results also support those reported by Durmus et al.\[16\] regarding the significant delay in latencies of waves III and V. However, we also revealed a significant prolongation of IPL III-V and I-V in diabetic subjects, which was not observed by them. The significant rise in latency of wave V and IPL I-V in T2DM patients, as reported by Habib et al.\[17\] and Ren et al.\[18\] was also observed in our study. However, we also revealed a significant rise in latency of waves III, IV and IPL III-V, which were not reported by Habib et al.

In the present study, the latency of waves I and II were found to be comparable between both the groups, indicating that the auditory nerve (Cranial Nerve VIII) transmission is normal in males with T2DM. In fact, prolongation of wave I is an inconsistent finding in literature as only a few authors have observed it in diabetic persons.\[14,17\] On the other hand, the delay in latencies of waves III, IV, V and IPL III-V, I-V which is indicative of a central conduction delay at the brainstem-to-midbrain level, is a more commonly observed finding, as already discussed. The delay in the central conduction time in diabetes may be related to the neurodegenerative changes occurring in these patients. The exact mechanism of neuronal degeneration in T2DM is uncertain. However, as suggested by some recent studies, the insulin resistance in T2DM, not only leads to a compromise in the cell survival, metabolism and neuronal plasticity, but also increases oxidative stress and apoptosis of neurons. Also, an increase in the ceramide generation and a subsequent rise in its trafficking across the blood brain barrier, promotes further insulin resistance and neurodegenerative changes in the brain of patients with T2DM.\[19\]

In our study, there was a non-significant positive correlation of BAEP latencies with both the duration of diabetes and FBG levels. The absence of a correlation between BAEP latencies and fasting blood glucose in diabetes would appear to rule out subclinical hypoglycemia as a source of delay in the transmission time. Also, the absence of a correlation between BAEP abnormalities and duration of diabetes may be attributed to the relatively shorter duration of diabetes in our patients (mean 5.68 ± 3.16 years). These findings have

### Table 4: Comparison of brainstem auditory evoked potentials latencies (in msec) between diabetic and control subjects

| BAEP latencies | Diabetic group Mean±SD | Control group Mean±SD | P value |
|----------------|------------------------|-----------------------|---------|
| **Right ear**  |                        |                       |         |
| I              | 1.64±0.42              | 1.62±0.15             | 0.79    |
| II             | 2.85±0.49              | 2.79±0.21             | 0.06    |
| III            | 3.78±0.53              | 3.55±0.14             | 0.03*   |
| IV             | 5.01±0.56              | 4.84±0.20             | 0.02*   |
| V              | 7.96±0.68              | 5.39±0.17             | 0.01*   |
| I-III          | 2.08±0.29              | 2.03±0.16             | 0.06    |
| III-V          | 2.10±0.72              | 1.84±0.16             | 0.03*   |
| I-V            | 4.15±0.71              | 3.86±0.21             | 0.02*   |
| **Left ear**   |                        |                       |         |
| I              | 1.68±0.38              | 1.63±0.15             | 0.82    |
| II             | 2.90±0.35              | 2.80±0.19             | 0.06    |
| III            | 3.74±0.36              | 3.53±0.16             | 0.03*   |
| IV             | 4.92±0.35              | 4.90±0.18             | 0.93    |
| V              | 5.88±0.42              | 5.46±0.23             | 0.009*  |
| I-III          | 2.05±0.31              | 2.06±0.17             | 0.87    |
| III-V          | 2.04±0.31              | 1.82±0.23             | 0.02*   |
| I-V            | 4.10±0.37              | 3.83±0.22             | 0.02*   |

*Significant (P<0.05).

### Table 5: Pearson’s correlation coefficient (r) between the brainstem auditory evoked potentials latencies, fasting blood glucose levels and duration of disease in T2DM patients

| BAEP latencies | Duration of disease | FBG levels |
|----------------|---------------------|------------|
| **Right ear**  |                     |            |
| I              | 0.012               | 0.042      |
| II             | 0.030               | 0.063      |
| III            | 0.038               | 0.192      |
| IV             | 0.134               | 0.320      |
| V              | 0.060               | 0.030      |
| I-III          | 0.010               | 0.199      |
| III-V          | 0.045               | 0.327      |
| I-V            | 0.036               | 0.186      |
| **Left ear**   |                     |            |
| I              | 0.019               | 0.192      |
| II             | 0.099               | 0.101      |
| III            | 0.083               | 0.012      |
| IV             | 0.131               | 0.199      |
| V              | 0.195               | 0.327      |
| I-III          | 0.122               | 0.320      |
| III-V          | 0.030               | 0.118      |
| I-V            | 0.177               | 0.210      |

*All the ‘r’ values are non significant for both right and left ear (P>0.05).
been confirmed by many other researchers,[13,16] but a few others have observed a significant correlation of BAEP abnormalities with the duration of diabetes, which may be due to the relatively longer duration of diabetes in their study subjects (mean duration > 10 years).[20,21] Some discrepancies between the results of this study and the ones previously mentioned can be explained by the fact that those studies used a different methodology, as well as different inclusion and exclusion criteria and also studied highly heterogeneous populations.

Keeping in mind the consistent rise in the global incidence of diabetes mellitus and the detrimental effect that it has on the hearing ability of an individual, it is suggested that BAEP testing may also be included in the litany of the routine screening procedures that are of vital importance in diabetes patients (e.g. eye fundus examination, microalbuminuria assessment), wherever it is possible. This is the most important clinical implication of this study.

**Study limitations**

An important limitation of our study was the use of fasting blood glucose (FBG) as an indicator of the chronic glyemic status of T2DM patients. We admit that FBG values vary on a daily basis, depending upon the glucose levels in blood and are better indicative of acute glyemia. HbA1c is a newer and a better parameter to assess chronic glyemia and long term complications of diabetes. However, due to the higher cost of this test and the poor financial condition of our patients, to which our hospital mainly caters, we were unable to carry out HbA1c testing in our patients. Also keeping in mind the results of many studies, done worldwide including India,[22-24] that have shown a strong, significant positive correlation of HbA1c and FBG levels in diabetics, we feel that FBG could be considered as an equally effective alternative to HbA1c, in the assessment of chronic glyemia.

Another limitation might be the relatively smaller sample size of this study, but this was the maximum number of the participants that we could get, who best fulfilled the study criteria, during the duration for which the study was carried out.

**Conclusion**

The results of this study clearly suggest that even though earlier on in the course of T2DM, a person might be unaware of any hearing impairment, yet degenerative changes so begin to appear at various levels in the central nervous system. It is possible to detect these subtle neurodegenerative changes, non-invasively and with fair accuracy, at initial stages of the disease itself, by using BAEP studies. Also in consideration of the relative lack of similar studies from the Indian subcontinent, which boasts of an extreme diversity in the socioeconomic status, dietary and lifestyle patterns, there is an urgent need to carry out more such studies on a regional basis in India. This would also help in standardizing the pattern of BAEP abnormalities in diabetes mellitus.

**Acknowledgement**

The authors are thankful to all the enrolled subjects, without whose active participation, this work would not have been possible. We are also grateful to the staff of the ENT and Clinical Biochemistry departments of the hospital, for all their help and support.

**References**

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
2. Alwin CP. Diabetes mellitus. In: Kasper DL, Braunwald E, Fauci AS, Hause SL, Longo DL, Jameson JL, editors. Harrison’s principles of internal medicine 16th ed. New York, NY: McGraw Hill Medical; 2005. p. 2152-80.
3. Wabe NT, Angamo MT, Hussein S. Medication adherence in diabetes mellitus and self management practices among type 2 diabetics in Ethiopia. N Am J Med Sci 2011;3:418-23.
4. Maia CA, Campos CA. Diabetes mellitus as etiological factor for hearing loss. Braz J Otorhinolaryngol 2005;71:208-14.
5. Jali MV, Kambar S, Jali SM, Gowda S. Familial early onset of type 2 diabetes mellitus and its complications. N Am J Med Sci 2009;1:377-80.
6. Imam M, Shehata OH. Subclinical central neuropathy in type 2 diabetes mellitus. Bull Alex Fac Med 2009;45:65-73.
7. Misra UK, Kalita J. Clinical Neurophysiology. 2nd ed. India: Elsevier Publications; 2006.
8. Biacabe B, Chevallier JM, Avan P, Bonfils P. Functional anatomy of auditory brainstem nuclei: Application to the anatomical basis of brainstem auditory evoked potentials. Auris Nasus Larynx 2001;28:85-94.
9. Ravecca F, Berrettini S, Bruschini L, Segnini G, Sellari-Franceschini S. Progressive sensorineural hearing loss: Metabolic, hormonal and vascular aetiology. Acta Otorhinolaryngol Ital 1998;18:42-50.
10. Das T, Kundu S, Mazumdar AK, Mukhopadhyay SC. Studies on central nervous system function in diabetes mellitus. J Indian Med Assoc 2001;84:86-9.
11. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33:S62-9.
12. Guideline 9C: Guidelines on short latency auditory evoked potentials. American Clinical Neurophysiological Society, 2008. (Accessed September 1, 2021, at http://www.acns.org/pdfs/Guideline%209C1.pdf).
13. Talebi M, Moosavi M, Mohamadzade NA, Roshandel M. Study on brainstem auditory evoked potentials in diabetes mellitus. Neurosciences (Riyadh) 2008;13:370-3.
14. Al-Azzawi LM, Mirza KB. The usefulness of brainstem auditory evoked potential in early diagnosis of cranial
neuropathy associated with diabetes mellitus. Electromyogr Clin Neurophysiol 2004;44:387-94.
15. Gupta R, Mohd A, Hasan SA, Siddiqi SS. Type 2 diabetes mellitus and auditory brainstem responses- a hospital based study. Indian J Endocrinol Metab 2010;14:9-11.
16. Durmus C, Yetiser S, Durmus O. Auditory brainstem evoked responses in insulin dependent (ID) and non insulin dependent (NID) diabetic subjects with normal hearing. Int J Audiol 2004;43:29-33.
17. Habib SS, Husain A, Omar SA, Al Drees AM. Brainstem auditory evoked potentials and electrocochleographic findings in patients with idiopathic sudden sensorineural hearing loss. J Coll Physicians Surg Pak 2011;21:415-9.
18. Ren J, Zhao P, Chen Li, Xu A, Brown SN, Xiao X. Hearing loss in middle age subjects with type 2 diabetes mellitus. Arch Med Res 2009;40:18-23.
19. de la Monte SM, Longato L, Tong M, Wands JR. Insulin resistance and neurodegeneration: Roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatits. Curr OpinInvestig Drugs 2009;10:1049‑60.
20. Rajendran S, Anandhalakshmi, Mythili B, Vishwanathan R. Evaluation of the incidence of sensorineural hearing loss in patients with type 2 diabetes mellitus. Int J Biol Med Res 2011;2:982-7.
21. Fawi GH, Khalifa GA, Kasim MA. Central and peripheral conduction abnormalities in diabetes mellitus. Egypt J Neurol Psychiatry Neurosurg 2005;42:209-21.
22. ManjunathGond BK, Bhavna N, Sarsina DO, Satisha TJ, Sweta S, Devaki RN. Relation of calculated HbA1c with fasting plasma glucose and duration and diabetes. Int J App Biol Pharm Tech 2011;2:58-61.
23. Peter R, Luzio SD, Dunseath G, Pauvaday V, Mustafa N, Owens DR. Relationship between HbA1c and indices of glucose tolerance derived from a standardised meal test in newly diagnosed treatment naive subjects with type 2 diabetes. Diabet Med 2006;23:990-5.
24. Ghazanfari Z, Haghdooest AA, Alizadeh SM, Atapour J, Zolala F. A comparison of HbA1c and fasting blood sugar tests in general population. Int J Prev Med 2010;1:187-94.